Aditx Therapeutics’ $9.6 Million Underwritten Public Offering


Sheppard Mullin advised Aditx Therapeutics, Inc. on the deal.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, announced the closing of its previously announced upsized $9.6 million underwritten public offering of 2,400,000 units, with each unit consisting of one share of common stock, one Series A-1 Warrant, and one Series B-1 Warrant.

The Sheppard Mullin deal team was led by partner Richard Friedman (Picture) and included associates Alex Yarbrough and Taylor Ashton.

Involved fees earner: Taylor Ashton – Sheppard Mullin; Richard Friedman – Sheppard Mullin; Alexander Yarbrough – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Aditx Therapeutics, Inc.;

Author: Ambrogio Visconti